Skip to main navigation Skip to search Skip to main content

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma

  • Praful Ravi
  • , Charlene Mantia
  • , Christopher Su
  • , Karl Sorenson
  • , Dean Elhag
  • , Nityam Rathi
  • , Ziad Bakouny
  • , Neeraj Agarwal
  • , Yousef Zakharia
  • , Brian A. Costello
  • , Rana R. McKay
  • , Vivek Narayan
  • , Ajjai Alva
  • , Bradley A. McGregor
  • , Xin Gao
  • , David F. McDermott
  • , Toni K. Choueiri

Research output: Contribution to journal › Article › peer-review

Abstract

Importance: Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the efficacy and safety of ICI rechallenge in mRCC is unknown. Objective: To evaluate the safety and efficacy of ICI rechallenge in patients with mRCC. Design, Setting, and Participants: This multicenter, retrospective cohort study included consecutive patients with mRCC from 9 institutions in the US who received at least 2 separate lines of ICI (ICI-1, ICI-2) between January 2012 and December 2019. Exposure: Receipt of an ICI (anticytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1, or anti-programmed cell death ligand 1), alone or in combination with other therapies, in at least 2 separate lines of therapy for mRCC. Main Outcomes and Measures: Investigator-assessed best overall response and immune-related adverse events. Results: A total of 69 patients were included. Median (range) age at diagnosis of mRCC was 61 (36-86) years. Of these, 50 were men and 19 were women. The most common therapies received at ICI-1 were single-agent ICI (n = 27 [39%]) or ICI in combination with targeted therapy (n = 29 [42%]), while at ICI-2, the most common therapies were single-agent ICI (n = 26 [38%]) or dual ICI (n = 22 [32%]). Most patients discontinued ICI-1 owing to disease progression (n = 50 [72%]) or toxic effects (n = 16 [23%]). The overall response rates at ICI-1 and ICI-2 were 37% and 23%, respectively. The likelihood of a response at ICI-2 was greatest among patients who had previously responded to ICI-1 (7 of 24 [29%]), although responses at ICI-2 were seen in those who had progressive disease as their best response following ICI-1 (3 of 14 [21%]) as well as in those who received single-agent ICI at ICI-2 (7 of 23 [30%]). Grade 3 or higher immune-related adverse events were seen in 18 patients (26%) and 11 patients (16%) at ICI-1 and ICI-2, respectively. There were no treatment-related deaths. Conclusions and Relevance: The findings of this multicenter cohort study suggest that ICI rechallenge in patients with mRCC may be safe and reasonably efficacious, with an overall response rate of 23%. Data from prospective studies are needed to validate these findings and determine the role of sequential ICI regimens in treatment of mRCC.

Original languageEnglish (US)
Pages (from-to)1606-1610
Number of pages5
JournalJAMA Oncology
Volume6
Issue number10
DOIs
StatePublished - Oct 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this